Page 390 - IJB-9-4

International Journal of Bioprinting Evolution of bioprinting

117. Krüger J, Groß R, Conzelmann C, et al., 2021, Drug 121. Agarwal K, Srinivasan V, Lather V, et al., 2022, Insights of
inhibition of SARS-CoV-2 replication in human 3D bioprinting and focusing the paradigm shift towards
pluripotent stem cell-derived intestinal organoids. Cell Mol 4D printing for biomedical applications. J Mater Res, 38(1):
Gastroenterol Hepatol, 11(4): 935–948. 112–141.
http://doi.org/10.1016/J.JCMGH.2020.11.003. http://doi.org/10.1557/S43578-022-00524-2.
118. Ben-David U, Siranosian B, Ha G, et al., 2018, Genetic 122. Tamay DG, Usal TD, Alagoz AS, et al., 2019, 3D and 4D
and transcriptional evolution alters cancer cell line drug printing of polymers for tissue engineering applications.
response. Nature, 560(7718): 325–330. Front Bioeng Biotechnol, 7(JUL): 164.

http://doi.org/10.1038/S41586-018-0409-3. http://doi.org/10.3389/FBIOE.2019.00164/BIBTEX.
119. Neufeld L, Yeini E, Reisman N, et al., 2021, Microengineered 123. Aprecia, 2015, Spritam, viewed March 02, 2023,
perfusable 3D-bioprinted glioblastoma model for in vivo
mimicry of tumor microenvironment. Sci Adv, 7(34): https://www.aprecia.com/technology/zipdose
eabi9119.
http://doi.org/10.1126/SCIADV.ABI9119.
120. Butcher DT, Alliston T, Weaver VM, 2009, A tense
situation: Forcing tumour progression. Nat Rev Cancer,
9(2): 108–122.
http://doi.org/10.1038/NRC2544.

Volume 9 Issue 4 (2023) 382 https://doi.org/10.18063/ijb.742